-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q2 Revenue $18.9M, vs. Street Est of $23.2M
4:33PM ET 8/11/2022 MT Newswires...
Quotes Snapshot > FBIO
Fortress Biotech Inc FBIO:NASDAQ
Last Price$1.25Cboe Real-Time Last Sale as of 1:59PM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.02(1.57%)
Bid (Size)$1.22 (200)
Ask (Size)$1.27 (300)
Day Low / High$1.19 - 1.29
Volume170.9 K
Read more news Recent News
-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q2 Loss $-0.10, vs. Street Est of $-0.08
4:32PM ET 8/11/2022 MT Newswires...
--Ladenburg Thalmann Starts Fortress Biotech at Buy With $6 Price Target
7:03AM ET 8/04/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Fortress Biotech Names David Jin as CFO
8:43AM ET 7/22/2022 MT NewswiresFortress Biotech (FBIO) on Friday said it appointed David Jin as chief financial officer, effective Aug. 16. Jin will also continue serving as the...
View all Commentary and Analysis
Fortress Biotech (FBIO) Investor Presentation - Slideshow
3:50PM ET 8/12/2022 Seeking AlphaFortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
4:45PM ET 8/11/2022 ZacksFortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively,...
Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript
9:05PM ET 8/09/2022 Seeking AlphaStocks To Watch: Retail Heavyweights Report, Block And Moderna Events
9:27AM ET 5/14/2022 Seeking AlphaCompany Profile
Business DescriptionFortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL. View company web site for more details
| Address | 1111 Kane Concourse Bay Harbor Islands, Florida 33154 |
| Phone | +1.781.652.4500 |
| Number of Employees | 88 |
| Recent SEC Filing | 08/11/2022 8-K |
| Chairman, President & Chief Executive Officer | Lindsay Allan Rosenwald |
| Chief Financial Officer, Secretary & Treasurer | Robyn M. Hunter |
| Senior Vice President-Biologics Operations | George C. Avgerinos |
| Director & Vice Chairman-Strategic Development | Michael Sean Weiss |
Company Highlights
| Price Open | $1.27 |
| Previous Close | $1.27 |
| 52 Week Range | $0.77 - 3.81 |
| Market Capitalization | $134.7 M |
| Shares Outstanding | 107.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/21/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.06 |
| Beta vs. S&P 500 | N/A |
| Revenue | $26.9 M |
| Net Profit Margin | -108.87% |
| Return on Equity | -95.07% |
Analyst Ratings as of 08/03/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |